Cliniphar SRL
Cliniphar reported total assets of €2.63m at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Jul 2026).
The score of Cliniphar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +8 % Total assets -32 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Cliniphar's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Jul 2026
- Year ended 31 Dec 2024filed on 31 Jul 2025
- Year ended 31 Dec 2023filed on 16 Aug 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 27 Jun 2022
Cliniphar's financial analysis
- Solvency96.6%sector median: 75.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Cliniphar
Cliniphar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0473.637.637
- VAT number
- BE0473637637
- Peppol
- Registered · 0208:0473637637 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 28 Dec 2000
- Registered office
- 3140 Keerbergen
- Latest accounts
- 2025 · filed on 31 Jul 2026
- Activity
- Diagnostic imaging services and medical laboratory activities (NACE 86910)
Cliniphar (SRL) has been based in Keerbergen since 2000, active in: diagnostic imaging services and medical laboratory activities. For 2025, it reports a net profit of 65,315 € and equity of €2.54m; its revenue is not published. Its solvency stands at 96.6%, above the median of its sector (75.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Cliniphar
Companies in the same business, of comparable size and area, outside its group.
- Apr. Boel A. Diagnostic imaging services and medical laboratory activities Merelbeke-Melle · balance sheet €2.31m
- Dr. Sabine Vergauwen Diagnostic imaging services and medical laboratory activities Bornem · balance sheet €2.18m
- Artsenpraktijk Sithova Diagnostic imaging services and medical laboratory activities Leuven · balance sheet €3.20m
- Willsint Diagnostic imaging services and medical laboratory activities Sint-Niklaas · balance sheet €2.06m
- Ghislain Dermatologie Diagnostic imaging services and medical laboratory activities Mons · balance sheet €1.99m
- Medisch Kabinet Dr. Jan Laenens - Huisarts Diagnostic imaging services and medical laboratory activities Aarschot · balance sheet €1.71m
- Oncurious Diagnostic imaging services and medical laboratory activities Brussels · balance sheet 160,462 €
- Chrometra Diagnostic imaging services and medical laboratory activities Kortenaken · balance sheet 97,221 €
Frequently asked questions about Cliniphar
What is the revenue of Cliniphar?
Cliniphar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Cliniphar?
In Belgium, the VAT number is the company number prefixed with BE: BE0473637637 for Cliniphar, if the company is VAT-registered. Its company number (CBE) is 0473.637.637.
Where is the registered office of Cliniphar?
According to the CBE register, the registered office of Cliniphar is in 3140 Keerbergen.
What is the equity of Cliniphar?
At the close of the 2025 financial year, the equity of Cliniphar amounts to 2,536,190 €, a solvency of 96.6% of total assets.
Who manages Cliniphar?
The register lists 1 active mandates at Cliniphar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Cliniphar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →